Anal Intraepithelial Neoplasia
4
Pipeline Programs
6
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
3
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
1100%
+ 5 programs with unclassified modality
Competitive Landscape
6 companies ranked by most advanced pipeline stage
ISA PharmaceuticalsNetherlands - Oegstgeest
1 program1
HPV-16 vaccinePhase 1/2Vaccine1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Sharp Therapeutics9-valent HPV vaccination
Inovio PharmaceuticalsElectroporation
ISA PharmaceuticalsHPV-16 vaccine
Finch TherapeuticsPhysical examination
Clinical Trials (4)
Total enrollment: 342 patients across 4 trials
HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL
Start: Sep 2022Est. completion: May 2026228 patients
Phase 2Unknown
VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions
Start: Sep 2018Est. completion: Jun 202544 patients
Phase 2Completed
Therapeutic HPV-16 Vaccination for the Treatment of Anal Dysplasia
Start: Aug 2013Est. completion: Dec 201740 patients
Phase 1/2Completed
COrSIcA: Disease Measurement
Start: Jul 2023Est. completion: Jul 202530 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
6 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.